Gustavo Monnerat: New Evidence on Adverse Effects Attributed to Statin Therapy
Gustavo Monnerat, Deputy Editor at The Lancet, shared a a post on LinkedIn:
“New Evidence on Adverse Effects Attributed to Statin Therapy
The Cholesterol Treatment Trialists just published acomprehensive individual participant data meta-analysis conducted on statin adverse effects, covering nearly 124,000 participants across 19 double-blind placebo-controlled trials.
Main results:
- Of 66 listed adverse outcomes, only 4 showed a statistical significance: liver enzyme elevations, urinary composition changes, and oedema
- No causal link was found for cognitive impairment, depression, sleep disturbance, sexual dysfunction, or peripheral neuropathy.
- Liver effects were dose-dependent
Statins remain one of the most impactful interventions in cardiovascular medicine
Caveats: Trial durations (median 4.5 years) may not capture very long-term or very rare effects.:
Title: Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
Authors: Christina Reith, Lisa Blackwell, Jonathan R Emberson, David Preiss, Enti Spata, Kelly Davies, Heather Halls, Charlie Harper, Lisa Holland, Kate Wilson, Robert Humphrey, Alistair J Roddick, Christopher P Cannon, Barry R Davis, Paul N Durrington, Shinya Goto, Graham A Hitman, G Kees Hovingh, Wolfgang Koenig, Vera Krane, Martin J Landray, Borislava Mihaylova, Connie Newman, Jeffrey L Probstfield, Marc S Sabatine, Naveed Sattar, Gregory G Schwartz, Andrew M Tonkin, Harvey D White, Jane Armitage, Anthony Keech, John Simes, Rory Collins, Colin Baigent, Elizabeth Barnes, Jordan Fulcher, William G Herrington, Adrienne Kirby, Rachel O’Connell, Pierre Amarenco, Hiroyuki Arashi, Philip Barter, D John Betteridge, Michael Blazing, Gerard J Blauw, Marc Bonaca, Jackie Bosch, Louise Bowman, Eugene Braunwald, Richard Bulbulia, Robert Byington, Robert Clarke, Michael Clearfield, Stuart Cobbe, Helen M Colhoun, Björn Dahlöf, James de Lemos, John R Downs, Bengt Fellström, Lawrence Fine, Marcus Flather, Ian Ford, Maria Grazia Franzosi, John Fuller, Curt Furberg, Robert Glynn, Uri Goldbourt, David Gordon, Antonio Gotto Jr, Richard Grimm, Ajay Gupta, C Morton Hawkins, Richard Haynes, Hallvard Holdaas, Jemma Hopewell, Alan Jardine, J Wouter Jukema, John JP Kastelein, Sharon Kean, Patricia Kearney, George Kitas, John Kjekshus, Genell Knatterud, Robert H Knopp, Michael Koren, John LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter Macfarlane, Stephen MacMahon, Aldo Maggioni, Roberto Marchioli, Ian Marschner, Lemuel Moyé, Heather Murray, Sabina Murphy, Andrew Neil, Enrico B Nicolis, Chris Packard, Sarah Parish, Terje R Pedersen, Richard Peto, Marc Pfeffer, Neil Poulter, Sara Pressel, Mahboob Rahman, Paul M Ridker, Michele Robertson, Frank Sacks, Roland Schmieder, Patrick W Serruys, Peter Sever, John Shaw, James Shepherd, Lara Simpson, Peter Sleight, Liam Smeeth, Luigi Tavazzi, Jonathan Tobert, Gianni Tognoni, Stella Trompet, John Varigos, Christoph Wanner, Hans Wedel, Stephen Weis, K Michael Welch, John Wikstrand, Lars Wilhelmsen, Stephen Wiviott, Junichi Yamaguchi, Robin Young, Salim Yusuf, Faiez Zannad
Read the Full Article on The Lancet
Find more posts on Hemostasis Today.
-
Mar 24, 2026, 17:12Ron DePinho: CRISPR Progress in Cellular Immunotherapy
-
Mar 24, 2026, 17:12Martine Gilard։ Women’s Heart Health as a National Priority
-
Mar 24, 2026, 17:11Erik Nelson։ Blood Vessels – The Silent System That Determines How You Age
-
Mar 24, 2026, 17:10Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
-
Mar 24, 2026, 17:09Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
-
Mar 24, 2026, 17:06Anita Brikman: PPTA Explores India’s Growing Plasma-Derived Medicines Industry
-
Mar 24, 2026, 17:01Victor Canata: Is Embolectomy the Best Treatment for Pulmonary Thromboembolism?
-
Mar 24, 2026, 16:57Hossam Qassem: The Stepwise Investigation Framework for ICU Hemoglobin Drop
-
Mar 24, 2026, 16:56Alan Nurden: Targeting Splice Site Variants in Alport Syndrome with Antisense Therapy